Quality of life (QOL) with sunitinib versus interferon-alfa (IFN-α) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): Final results Multivariate analysis performed without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback